Population-Based Medication Risk Stratification and Personalized Medication Risk Score
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2018/058405, filed Oct 31, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,361,856 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score In force · High confidence | Tabula Rasa Healthcare, Inc. | In force | High confidence | ||
| US 12,159,723 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score In force · High confidence | Tabula Rasa Healthcare, Inc. | In force | High confidence | ||
| Application 17/837,841 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score Abandoned Abandoned Nov 30, 2023 | Tabula Rasa Healthcare, Inc. | Abandoned | Abandoned Nov 30, 2023 | not computed | |
| Application 18/960,848 | Population-Based Medication Risk Stratification and Personalized Medication Risk Score Pending Not granted | Tabula Rasa Healthcare, Inc. | Pending | Not granted | not computed |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Tabula, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.